Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scottish funding to develop single blood test:

This article was originally published in Clinica

Executive Summary

The UK's University of Edinburgh has received funding to develop a single blood screening test, under the Scottish Executive's Proof of Concept Fund. The award announced today (February 28 2003) will be used to develop a system that researchers believe can simplify the process involved in processing the estimated 25 million blood donations screened worldwide every year. These currently undergo multiple testing before they are deemed safe; a single test would result in greater efficiency and, therefore, significant cost savings. The research will involve the Scottish National Blood Transfusion Service and the Scottish Centre for Genomic Technology and Informatics. The £33m ($52m) Proof of Concept Fund has financed 118 "leading-edge technology" projects in academic institutions, with the aim of promoting their commercial development, since it was set up in 1999.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT061334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel